Related Experiment Video
Updated: Apr 26, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
2014 Update of the drug resistance mutations in HIV-1
Annemarie M Wensing1, Vincent Calvez2, Huldrych F Günthard3
1University of Medical Center Utrecht, The Netherlands.
Abstract:
This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.
Related Concept Videos
Viral Mutations
Treatment Resistant Cancers
Retrovirus Life Cycles
Mutations in Microorganisms
Mechanism of Antibiotic Resistance in MRSA
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

